RON in hepatobiliary and pancreatic cancers:Pathogenesis and potential therapeutic targets  

作　　者：Shao-Long Chen Guo-Ping Wang Dan-Rong Shi Shu-Hao Yao Ke-Da Chen Hang-Ping Yao 

机构地区：[1]Shulan International Medical College,Zhejiang Shuren University,Hangzhou 310000,Zhejiang Province,China [2]Department of Surgical Oncology,The Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310000,Zhejiang Province,China [3]State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310000,Zhejiang Province,China [4]Department of Stomatology,Wenzhou Medical University Renji College,Wenzhou 325035,Zhejiang Province,China

出　　处：《World Journal of Gastroenterology》2021年第20期2507-2520,共14页世界胃肠病学杂志（英文版）

基　　金：National Natural Sciences Foundation of China,No.81872883;Zhejiang Major Medical Health&Sciences Technology Foundation Projects,No.WKJ-ZJ-13.

摘　　要：The receptor protein tyrosine kinase RON belongs to the c-MET proto-oncogene family.Research has shown that RON has a role in cancer pathogenesis,which places RON on the frontline of the development of novel cancer therapeutic strategies.Hepatobiliary and pancreatic(HBP)cancers have a poor prognosis,being reported as having higher rates of cancer-related death.Therefore,to combat these malignant diseases,the mechanism underlying the aberrant expression and signaling of RON in HBP cancer pathogenesis,and the development of RON as a drug target for therapeutic intervention should be investigated.Abnormal RON expression and signaling have been identified in HBP cancers,and also act as tumorigenic determinants for HBP cancer malignant behaviors.In addition,RON is emerging as an important mediator of the clinical prognosis of HBP cancers.Thus,not only is RON significant in HBP cancers,but also RON-targeted therapeutics could be developed to treat these cancers,for example,therapeutic monoclonal antibodies and small-molecule inhibitors.Among them,antibody-drug conjugates have become increasingly popular in current research and their potential as novel anti-cancer biotherapeutics will be determined in future clinical trials.

关 键 词：RON Signal transduction HEPATOBILIARY Pancreatic neoplasms Molecular targeted therapy 

分 类 号：R735.9[医药卫生—肿瘤] R735.7[医药卫生—临床医学] R735.8